New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy.
Details
Download: 34910287_BIB_EFFF2E71408F.pdf (741.42 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_EFFF2E71408F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy.
Journal
High blood pressure & cardiovascular prevention
ISSN
1179-1985 (Electronic)
ISSN-L
1120-9879
Publication state
Published
Issued date
03/2022
Peer-reviewed
Oui
Volume
29
Number
2
Pages
125-135
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
With chronic kidney disease (CKD) being a global arising health problem, strategies for delaying kidney disease progression and reducing the high cardiovascular risk inherent to CKD, are the main objectives of the actual management of patients with kidney diseases. In these patients, the control of arterial hypertension is essential, as high blood pressure (BP) is a strong determinant of worst cardiovascular and renal outcomes. Achieving target blood pressures recommended by international guidelines is mandatory and often demands a multiple levels management, including several pharmacological and lifestyle measures. Even in the presence of adequate BP control, the residual cardiovascular risk remains high. In this respect, the recent demonstration that novel agents such as sodium glucose transporter 2 (SGLT2) inhibitors or the new non-steroidal mineralocorticoid antagonist finerenone can retard the progression of kidney diseases and reduce cardiovascular mortality on top of standard of care treatment with renin-angiotensin system inhibitors represent enormous progresses. These studies also demonstrate that cardiovascular and renal protection can be obtained beyond blood pressure control. Other promising novelties are still to come such as renal denervation and endothelin receptor antagonists in the setting of diabetic and non-diabetic kidney diseases. In the present review, we shall discuss the classic and the new aspects for the management of hypertension in CKD, integrating the new data from recent clinical studies.
Keywords
Antihypertensive Agents/adverse effects, Blood Pressure, Humans, Hypertension/diagnosis, Hypertension/drug therapy, Renal Insufficiency, Chronic/complications, Renal Insufficiency, Chronic/diagnosis, Renal Insufficiency, Chronic/epidemiology, Renal Replacement Therapy, Blockers of the renin-angiotensin, Calcium antagonists, Chronic kidney disease, Diuretics, Endothelin antagonists, Finerenone, Hypertension, SGLT2 inhibitors
Pubmed
Web of science
Open Access
Yes
Create date
20/12/2021 12:35
Last modification date
23/11/2022 7:16